

Fujifilm's Irvine technology expands assisted reproductive technology product portfolio in China

27 February 2024 | News

Fujifilm Owen Technology will provide inventory for three products in China in 2024

Fujifilm Irvine Technologies, a leader in the innovation and manufacturing of cell culture solutions for the global life sciences and medical markets, has announced its assisted reproductive technology in China (ART) product portfolio has been expanded.

These new products represent key market growth opportunities in the region and respond to growing demand for the company's expertise in a complete range of media solutions and specialised technical support related to in vitro fertilisation (IVF) workflows. These three products are sold through Fujifilm (China) Investment Co., Ltd.

Previously, Fujifilm Irvine Technologies only provided a small number of products for in vitro fertilization (IVF) andrology and gamete and embryo processing solutions in China. The recent approval from the National Medical Products Administration (NMPA) expands the company's product portfolio in China into embryo culture media and meets the evolving needs of customers in the assisted reproduction market at every step of the IVF process.

While CSCM-C embryo culture medium is a new solution, an uninterrupted culture system designed specifically for days 5 and 6 of in vitro fertilization (IVF); Embryo Culture Oil is a sterile, light mineral oil designed to protect small volumes of culture fluid; and Arctic Sperm Cryopreservation Solution is an optimised cryopreservation solution used to support the freezing and thawing of sperm cells in in vitro fertilization and completes Fujifilm Irvine Technologies' andrology product portfolio in China.